Skip to main content

Augmenting Meds With Phone App Boosts Opioid Addiction Recovery Success

Medically reviewed by Carmen Pope, BPharm. Last updated on Jan 3, 2025.

via HealthDay

THURSDAY, Jan. 2, 2025 -- Augmenting medication for opioid use disorder (MOUD) with smartphone app-based contingency management (CM) is beneficial for uninsured or underinsured adults, according to a study published online Dec. 2 in JAMA Network Open.

Elise N. Marino, Ph.D., from the University of Texas Health Science Center at San Antonio, and colleagues examined whether augmenting MOUD with app-based CM is associated with days of opioid use at the end of treatment in a retrospective cohort study. The cohort included 600 individuals aged 18 years or older who were uninsured or underinsured and chose to receive MOUD only or MOUD plus CM delivered via a smartphone app (300 in each treatment group). On achieving their self-chosen recovery goals, participants who chose to receive app-based CM received monetary incentives.

The researchers found that compared with those who chose to receive MOUD only, those who chose to receive MOUD plus app-based CM reported significantly fewer days of opioid use at the end of treatment (mean duration, 8.4 versus 12.0 days; β = −6.10). Patients who chose to receive MOUD plus app-based CM were more likely to stay in treatment for longer than those who chose to receive MOUD only, according to retention analyses (mean duration, 290.2 versus 236.1 days; β = 51.91).

"Despite the challenges of engaging patients in other app-based interventions, adding recovery-oriented, app-based CM may be one way to enhance clinical care and meet the growing needs of historically underserved patients taking MOUD," the authors write.

One author received grants from KIOS/Biomedical Development Corp.

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Read this next

One in 10 Undergoing Early Cancer Surgery Have New Persistent Opioid Use

MONDAY, Sept. 8, 2025 -- More than one in 10 veterans undergoing surgery for early-stage cancer develop new persistent opioid use, according to a study published online Sept. 8 in...

2000 to 2023 Saw Rise in Pediatric Exposure to Medications, Supplements

MONDAY, Sept. 8, 2025 -- From 2000 to 2023, the rate of exposure to medications, dietary supplements, and psychoactive substances increased among children aged 6 to 12 years...

Buprenorphine Available at 39.4 Percent of U.S. Pharmacies in 2023

WEDNESDAY, Sept. 3, 2025 -- From 2017 to 2023, there was an increase in buprenorphine availability overall, reaching 39.4 percent in 2023, according to a study published online...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.